1. 474PA novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. (23rd October 2018) Authors: Seufferlein, T; Lausser, L; Stein, A; Prager, G; Kasper, S; Niedermeier, M; Müller, L; Kubicka, S; König, A-O; Büchner-Steudel, P; Wille, K; Perkhofer, L; Hann, A; Berger, A W; Arnold, D; Kestler, H; Ettrich, T J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 564PTRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO. (23rd October 2018) Authors: Ettrich, T J; Berger, A W; Decker, T; Hofheinz, R D; Heinemann, V; Hoffmann, T; Hebart, H F; Herrmann, T; Hannig, C-V; Büchner-Steudel, P; Bartholomäus, H; Güthle, M; Perkhofer, L; Seufferlein, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗